CL2019001106A1 - Composición para aliviar o tratar el dolor. - Google Patents

Composición para aliviar o tratar el dolor.

Info

Publication number
CL2019001106A1
CL2019001106A1 CL2019001106A CL2019001106A CL2019001106A1 CL 2019001106 A1 CL2019001106 A1 CL 2019001106A1 CL 2019001106 A CL2019001106 A CL 2019001106A CL 2019001106 A CL2019001106 A CL 2019001106A CL 2019001106 A1 CL2019001106 A1 CL 2019001106A1
Authority
CL
Chile
Prior art keywords
composition
pharmaceutical composition
present
relieve
treat pain
Prior art date
Application number
CL2019001106A
Other languages
English (en)
Inventor
Sujeong Kim
Heonsik Choi
Yejin Kwon
Minjung Kim
Minju Kim
Daewook Kim
Jangjoon Park
Jongho Cho
Soondong Lee
Joonsung Kim
Yeomoon Sim
Original Assignee
Kolon Life Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kolon Life Science Inc filed Critical Kolon Life Science Inc
Publication of CL2019001106A1 publication Critical patent/CL2019001106A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/30—Animals modified by surgical methods
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN PARA ALIVIAR O TRATAR EL DOLOR. UNA COMPOSICIÓN FARMACÉUTICA DE LA PRESENTE INVENCIÓN CONTIENE DOS O MÁS GENES SELECCIONADOS DEL GRUPO QUE CONSISTE EN GAD, IL-10 Y UN GEN QUE CODIFICA GDNF. LA COMPOSICIÓN FARMACÉUTICA DE LA PRESENTE INVENCIÓN EXHIBE UN EXCELENTE EFECTO ANALGÉSICO EN UNA DOSIS MÁS BAJA QUE LA DE LA ADMINISTRACIÓN INDIVIDUAL, YA QUE LOS GENES SE ADMINISTRAN DE FORMA CONJUNTA, LO CUAL PERMITE REDUCIR SUS EFECTOS SECUNDARIOS CONVENCIONALES Y SU TOXICIDAD. POR LO TANTO, LA COMPOSICIÓN FARMACÉUTICA DE LA PRESENTE INVENCIÓN PUEDE RESULTAR ÚTIL PARA ALIVIAR O TRATAR EL DOLOR.
CL2019001106A 2016-10-31 2019-04-23 Composición para aliviar o tratar el dolor. CL2019001106A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160143519 2016-10-31

Publications (1)

Publication Number Publication Date
CL2019001106A1 true CL2019001106A1 (es) 2019-08-16

Family

ID=62023801

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001106A CL2019001106A1 (es) 2016-10-31 2019-04-23 Composición para aliviar o tratar el dolor.

Country Status (14)

Country Link
US (1) US20190255152A1 (es)
EP (1) EP3533471B1 (es)
JP (1) JP6957614B2 (es)
KR (2) KR20190067815A (es)
CN (1) CN110461367B (es)
AU (1) AU2017351914B2 (es)
BR (1) BR112019008788A2 (es)
CA (2) CA3123063C (es)
CL (1) CL2019001106A1 (es)
ES (1) ES2905227T3 (es)
RU (1) RU2725830C1 (es)
SA (1) SA519401667B1 (es)
SG (1) SG11201903517RA (es)
WO (1) WO2018080277A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019363593A1 (en) * 2018-10-25 2021-04-29 Takeda Pharmaceutical Company Limited AAV triple-plasmid system
WO2020172631A2 (en) 2019-02-21 2020-08-27 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
CA3180304A1 (en) * 2020-05-28 2021-12-02 Kenan Christopher GARCIA Engineered interleukin-10 polypeptides and uses thereof
JP7659345B2 (ja) * 2021-03-12 2025-04-09 コーロン ライフ サイエンス インコーポレイテッド 神経変性疾患の予防または治療用組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
AU2005302408B2 (en) * 2004-10-28 2012-08-09 The Government of the United States of America as represented by the Department of Veterans Affairs Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
RU2433825C2 (ru) * 2004-12-06 2011-11-20 Медисинова, Инк. Способ лечения невропатической боли и связанных с ней синдромов
CA2610164A1 (en) * 2005-05-31 2006-12-07 Neurologix, Inc. Novel glutamic acid decarboxylase (gad) chimera and methods of use
WO2008010637A1 (en) * 2006-07-19 2008-01-24 Industry-Academic Cooperation Foundation, Yonsei University Composition for attenuating neuropathic pain comprising a recombinant vector expressing gad65
KR20080007968A (ko) * 2006-07-19 2008-01-23 연세대학교 산학협력단 Ｇａｄ65를 발현하는 재조합 벡터를 포함하는 신경병증성통증 완화용 조성물
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101586096A (zh) * 2008-05-21 2009-11-25 王尚武 一种共表达人源谷氨酸脱羧酶和细胞因子的重组病毒
EP2457579A1 (en) * 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
KR20150080033A (ko) * 2011-02-08 2015-07-08 애브비 인코포레이티드 골관절염 및 통증의 치료 방법
KR20170034701A (ko) * 2015-09-21 2017-03-29 코오롱생명과학 주식회사 통증 치료용 조성물

Also Published As

Publication number Publication date
CA3123063C (en) 2025-08-05
JP2019537595A (ja) 2019-12-26
KR102445192B1 (ko) 2022-09-20
WO2018080277A1 (ko) 2018-05-03
CA3041980C (en) 2023-06-13
EP3533471A1 (en) 2019-09-04
CA3123063A1 (en) 2018-05-03
CN110461367A (zh) 2019-11-15
AU2017351914A1 (en) 2019-05-23
ES2905227T3 (es) 2022-04-07
BR112019008788A2 (pt) 2019-07-16
SG11201903517RA (en) 2019-05-30
EP3533471A4 (en) 2020-05-06
RU2725830C1 (ru) 2020-07-06
AU2017351914B2 (en) 2020-09-10
CA3041980A1 (en) 2018-05-03
KR20210107140A (ko) 2021-08-31
CN110461367B (zh) 2023-05-26
US20190255152A1 (en) 2019-08-22
EP3533471B1 (en) 2022-01-19
KR20190067815A (ko) 2019-06-17
SA519401667B1 (ar) 2023-01-11
JP6957614B2 (ja) 2021-11-02

Similar Documents

Publication Publication Date Title
ECSP23096498A (es) Restos de administración terapéutica novedosos y usos de estos
CO2018012482A2 (es) Formulaciones de un inhibidor de lsd1
CL2019000821A1 (es) Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
CL2020000747A1 (es) Formulaciones de niraparib.
CL2018001404A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos.
CL2019003091A1 (es) Terapia de combinación.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
ECSP20057847A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CO2019009722A2 (es) Dendrímeros terapéuticos
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
BR112018001292A2 (pt) métodos para melhor liberação de agentes ativos a tumores
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
MX2018002446A (es) Compuestos heterociclicos fusionados como moduladores s1p.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2018000611A (es) Sistemas mejorados de entrega de nanoparticula.
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
ECSP18002561A (es) Sales y profármacos de 1-metil-d-triptófano
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
MX2021008941A (es) Moduladores gpr35.
CL2018001631A1 (es) Compuestos de dihidroquinolinsulfonamida de alquilo